ERBB2 and neoplasm: A larger proportion of patients had tumor size smaller than 30 mm (59.9%), without lymphovascular invasion (46.0%), absence of node involvements (50.9%), positive ER and PR status (57.1% and 49.8%), and negative HER-2 status (51.4%).